Personalised medicine is driving a fundamental shift in clinical trials, where the focus is increasingly on tailoring treatments to the unique biology and circumstances of each patient. As personalised medicine continues to evolve, the traditional one-size-fits-all model of randomised controlled trials (RCTs) is being complemented by approaches that emphasise individual variability in genes, environment, and lifestyle. This shift is underpinned by advances in molecular biology, bioinformatics, and clinical research methodologies, enabling a more nuanced understanding of disease and patient-specific responses to treatments.
What is Personalised Medicine?
The concept of personalised medicine is not new, but its rise to prominence within clinical trials reflects a broader cultural and technological shift in healthcare. Historically, RCTs have served as the gold standard for evaluating treatment efficacy. While these trials offer population-level insights, they fail to account for the biological heterogeneity that often influences patient responses. Personalised medicine, by contrast, aims to provide bespoke treatment plans that maximise efficacy and minimise side effects for individual patients.
Nicholas J. Schork's landmark article Personalised Medicine: Time for One-Person Trials published in Nature (2015) argued that traditional trial designs are ill-suited for capturing the complexities of individual variability. He advocated for "one-person trials," also known as N of 1 trials, as a superior approach to testing therapeutic interventions on a single patient using multiple crossover periods. Unlike traditional RCTs, where patients are randomly allocated to a treatment or control group, N of 1 trials involve alternating treatments in the same individual to determine their unique response to the treatment. This trial design provides a more direct understanding of treatment efficacy and adverse effects for the individual, contributing to a paradigm shift in the way clinical trials are conducted.
How Does Personalised Medicine Work?
Personalised medicine operates by leveraging individual patient data - primarily genetic, molecular, and clinical information - to tailor treatment strategies. At the heart of this approach lies genomic profiling, which identifies specific genetic mutations or variations that influence disease risk, progression, and treatment response. These molecular markers allow clinicians to predict how a patient might respond to certain therapies, enabling the selection of treatments that are most likely to be effective.
In practice, personalised medicine often involves the integration of advanced diagnostic tools to map a patient's unique genetic makeup. Coupled with bioinformatics, this data is analysed to identify actionable targets, such as overexpressed genes or aberrant signalling pathways, that can be addressed with precision therapies. Moreover, patient-specific factors such as age, lifestyle, and co-morbidities are taken into account, further refining the therapeutic approach. This personalised method stands in stark contrast to the traditional "trial-and-error" model of treatment selection often used in healthcare, offering a more targeted, efficient pathway to optimal patient care.
N of 1 Trials: The Pinnacle of Personalisation
N of 1 trials are often considered the epitome of personalised medicine, as noted by Joyce P. Samuel and colleagues in N-of-1 Trials: The Epitome of Personalised Medicine? (2015). These trials allow for the comparison of different treatments within the same patient, offering real-time, individualised data on the best course of action. N of 1 trials are recognised as the highest level of evidence for making treatment decisions according to the Oxford Centre for Evidence-Based Medicine levels of evidence published in 2011. By leveraging frequent feedback loops, N of 1 trials reduce uncertainty in treatment outcomes, enabling clinicians to optimise therapy based on the unique response profile of the patient. One significant advantage of N of 1 trials lies in their flexibility. Their flexibility in design is particularly valuable in cases where treatments need to be highly tailored, such as in patients with rare diseases or conditions that exhibit significant phenotypic variability. It also allows this design to be used in a range of diverse clinical contexts.
The Integration of Genomics and Data Analytics
The rise of personalised medicine would not be possible without the integration of genomic data and advanced bioinformatics tools. Next-generation sequencing technologies have revolutionised our ability to map the human genome and identify biomarkers that predict disease risk or therapeutic response. As Goetz and Schork discuss in Personalised Medicine: Motivation, Challenges, and Progress (2018), genomics plays a crucial role in pinpointing molecular pathways that could be targeted for treatment. By integrating genomic data with clinical information, researchers can identify subgroups of patients who are likely to benefit from specific interventions, thus refining trial design and reducing the risk of adverse effects.
In addition to genomics, the rise of machine learning and AI-powered analytics has further propelled the field of personalised medicine. These tools enable the processing of vast datasets, uncovering hidden patterns and correlations that may influence treatment outcomes. This data-driven approach allows for more precise stratification of patient populations and identification of those who may respond to a certain treatment.
Overcoming Challenges in Personalised Medicine
Despite its potential, integrating personalised medicine into clinical research presents several challenges. For one, the regulatory framework surrounding trials remains underdeveloped. Traditional RCTs are still favoured by regulatory bodies due to their established methodological features and large sample sizes. Ensuring that pooled N of 1 trials meet the rigorous standards required for regulatory approval will be crucial in fostering their widespread adoption.
Furthermore, the cost of some personalised medicine trials remains a significant barrier. Genomic sequencing and the development of individualised therapies can be resource-intensive, limiting access for certain patient populations. Additionally, the complexity of trial designs that incorporate genomic and phenotypic variability requires advanced statistical methods, which can be difficult to implement at scale. However, as Samuel et al. (2023) point out, the benefits of personalised clinical trial approaches far outweigh the challenges.
The Future of Clinical Trials: Personalised and Data-Driven
The rise of personalised medicine marks a pivotal moment in the evolution of clinical trials. As researchers continue to integrate genomics, bioinformatics, and AI into trial designs, the future of clinical research will be one that prioritises patient individuality over population averages. While challenges remain - particularly in terms of regulatory acceptance and the cost of genomic sequencing and development of individualised therapies - there is little doubt that personalised medicine will continue to shape the landscape of clinical trials. As Schork and Goetz emphasise, personalised medicine is not merely a trend but a necessary evolution in healthcare, one that has the potential to transform how we design, conduct, and interpret clinical research. In this era of personalised medicine, the ultimate goal is clear: to deliver the right treatment, to the right patient, at the right time. And with the growing adoption of N of 1 trials and personalised approaches, that goal is now within reach.
N-of-1 Hub is a world-leading company that specialises in designing, conducting and analysing personalised clinical studies using single-case designs. N-of-1 Hub provides consulting services and workshops/courses for companies, clinicians, researchers, and healthcare consumers in personalised clinical studies using single-case designs. N-of-1 Hub also offers data management and analysis services and coaching in single-case designs.
For further information about N-of-1 Hub, and to discuss your study needs, please contact us
References
Goetz, L. H., & Schork, N. J. (2018). Personalized medicine: Motivation, challenges, and progress. Fertility and Sterility, 109(6), 952–963. https://doi.org/10.1016/j.fertnstert.2018.05.006
Samuel, J. P., Wootton, S. H., & Tyson, J. E. (2015). N-of-1 trials: The epitome of personalized medicine? Pediatric Research, 29 April. https://doi.org/10.1038/nature.2015.520.609–611.
Schork, N. J. (2015). Personalized medicine: Time for one-person trials. Nature, 520(609–611). https://doi.org/10.1038/nature.2015.609